Abstract
BackgroundThere is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD.MethodsAn online survey was conducted among Japanese patients with IBD (n = 1035). Socioeconomic as well as treatment related information was collected. Logistic regression was applied to analyze the determinants of biologic treatment.ResultsYounger age (≤ 40 years vs. > 65 years; OR:0.24), time since diagnosis (< 2 years vs. < 15 years; OR: 4.16), surgical history (OR:1.98) and visiting university hospitals (university hospitals vs. clinics; OR: 0.47) were associated with biologic treatment for Japanese IBD patients.ConclusionsCurrently, biologics have been used in younger IBD patients which may give rise to the presence of an age bias in biologic treatment. Further studies are required to confirm these results and to define appropriate IBD patients who should be treated with biologic agent.
Highlights
There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan
To calculate factors associated with a treatment with biologics, we performed adjusted logistic regressions and reported the results as odds ratios (OR) with 95% confidence intervals (CI)
COPD, chronic obstructive pulmonary disease; OA, osteoarthritis; RA, rheumatoid arthritis; M JPY, million Japanese Yen; SD, standard deviation. To our knowledge, this is the first study to determine the factors associated with the use of biologics for the treatment of Japanese patients with IBD
Summary
There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD. In Japan, the prevalence of UC is 140,000 and that of CD 40,000 according to the Ministry of Health Labor and Welfare. Those numbers do not include patients with mild to moderate IBD and the actual number of IBD patients in Japan is estimated to be 20% to 40% higher [3]. IBD constitutes a significant burden to patients and it has been shown that Japanese patients with IBD face a four times higher risk
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
